Global Oligonucleotide-based Therapies Market Growth (Status and Outlook) 2025-2031

September 2025 | 92 pages | ID: G7C60FCA8EB2EN
LP Information

Abstracts

According to this study, the global Oligonucleotide-based Therapies market size will reach US$ 9362 million by 2031.

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.

Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.

Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.

LPI (LP Information)' newest research report, the “Oligonucleotide-based Therapies Industry Forecast” looks at past sales and reviews total world Oligonucleotide-based Therapies sales in 2024, providing a comprehensive analysis by region and market sector of projected Oligonucleotide-based Therapies sales for 2025 through 2031. With Oligonucleotide-based Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oligonucleotide-based Therapies industry.

This Insight Report provides a comprehensive analysis of the global Oligonucleotide-based Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oligonucleotide-based Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oligonucleotide-based Therapies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oligonucleotide-based Therapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oligonucleotide-based Therapies.

This report presents a comprehensive overview, market shares, and growth opportunities of Oligonucleotide-based Therapies market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Antisense Oligonucleotide
• Aptamer
• Other

Segmentation by Application:

• Neuromuscular Diseases
• Hepatic VOD
• Other

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Biogen
• Sarepta Therapeutics
• Jazz Pharmaceuticals
• Bausch & Lomb
• Alnylam Pharmaceuticals
• Dynavax Technologies
• Kastle therapeutics
• Akcea Therapeutics

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Oligonucleotide-based Therapies Market Size (2020-2031)
  2.1.2 Oligonucleotide-based Therapies Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Oligonucleotide-based Therapies by Country/Region (2020, 2024 & 2031)
2.2 Oligonucleotide-based Therapies Segment by Type
  2.2.1 Antisense Oligonucleotide
  2.2.2 Aptamer
  2.2.3 Other
2.3 Oligonucleotide-based Therapies Market Size by Type
  2.3.1 Oligonucleotide-based Therapies Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Oligonucleotide-based Therapies Market Size Market Share by Type (2020-2025)
2.4 Oligonucleotide-based Therapies Segment by Application
  2.4.1 Neuromuscular Diseases
  2.4.2 Hepatic VOD
  2.4.3 Other
2.5 Oligonucleotide-based Therapies Market Size by Application
  2.5.1 Oligonucleotide-based Therapies Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Oligonucleotide-based Therapies Market Size Market Share by Application (2020-2025)

3 OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE BY PLAYER

3.1 Oligonucleotide-based Therapies Market Size Market Share by Player
  3.1.1 Global Oligonucleotide-based Therapies Revenue by Player (2020-2025)
  3.1.2 Global Oligonucleotide-based Therapies Revenue Market Share by Player (2020-2025)
3.2 Global Oligonucleotide-based Therapies Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 OLIGONUCLEOTIDE-BASED THERAPIES BY REGION

4.1 Oligonucleotide-based Therapies Market Size by Region (2020-2025)
4.2 Global Oligonucleotide-based Therapies Annual Revenue by Country/Region (2020-2025)
4.3 Americas Oligonucleotide-based Therapies Market Size Growth (2020-2025)
4.4 APAC Oligonucleotide-based Therapies Market Size Growth (2020-2025)
4.5 Europe Oligonucleotide-based Therapies Market Size Growth (2020-2025)
4.6 Middle East & Africa Oligonucleotide-based Therapies Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Oligonucleotide-based Therapies Market Size by Country (2020-2025)
5.2 Americas Oligonucleotide-based Therapies Market Size by Type (2020-2025)
5.3 Americas Oligonucleotide-based Therapies Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Oligonucleotide-based Therapies Market Size by Region (2020-2025)
6.2 APAC Oligonucleotide-based Therapies Market Size by Type (2020-2025)
6.3 APAC Oligonucleotide-based Therapies Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Oligonucleotide-based Therapies Market Size by Country (2020-2025)
7.2 Europe Oligonucleotide-based Therapies Market Size by Type (2020-2025)
7.3 Europe Oligonucleotide-based Therapies Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Oligonucleotide-based Therapies by Region (2020-2025)
8.2 Middle East & Africa Oligonucleotide-based Therapies Market Size by Type (2020-2025)
8.3 Middle East & Africa Oligonucleotide-based Therapies Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL OLIGONUCLEOTIDE-BASED THERAPIES MARKET FORECAST

10.1 Global Oligonucleotide-based Therapies Forecast by Region (2026-2031)
  10.1.1 Global Oligonucleotide-based Therapies Forecast by Region (2026-2031)
  10.1.2 Americas Oligonucleotide-based Therapies Forecast
  10.1.3 APAC Oligonucleotide-based Therapies Forecast
  10.1.4 Europe Oligonucleotide-based Therapies Forecast
  10.1.5 Middle East & Africa Oligonucleotide-based Therapies Forecast
10.2 Americas Oligonucleotide-based Therapies Forecast by Country (2026-2031)
  10.2.1 United States Market Oligonucleotide-based Therapies Forecast
  10.2.2 Canada Market Oligonucleotide-based Therapies Forecast
  10.2.3 Mexico Market Oligonucleotide-based Therapies Forecast
  10.2.4 Brazil Market Oligonucleotide-based Therapies Forecast
10.3 APAC Oligonucleotide-based Therapies Forecast by Region (2026-2031)
  10.3.1 China Oligonucleotide-based Therapies Market Forecast
  10.3.2 Japan Market Oligonucleotide-based Therapies Forecast
  10.3.3 Korea Market Oligonucleotide-based Therapies Forecast
  10.3.4 Southeast Asia Market Oligonucleotide-based Therapies Forecast
  10.3.5 India Market Oligonucleotide-based Therapies Forecast
  10.3.6 Australia Market Oligonucleotide-based Therapies Forecast
10.4 Europe Oligonucleotide-based Therapies Forecast by Country (2026-2031)
  10.4.1 Germany Market Oligonucleotide-based Therapies Forecast
  10.4.2 France Market Oligonucleotide-based Therapies Forecast
  10.4.3 UK Market Oligonucleotide-based Therapies Forecast
  10.4.4 Italy Market Oligonucleotide-based Therapies Forecast
  10.4.5 Russia Market Oligonucleotide-based Therapies Forecast
10.5 Middle East & Africa Oligonucleotide-based Therapies Forecast by Region (2026-2031)
  10.5.1 Egypt Market Oligonucleotide-based Therapies Forecast
  10.5.2 South Africa Market Oligonucleotide-based Therapies Forecast
  10.5.3 Israel Market Oligonucleotide-based Therapies Forecast
  10.5.4 Turkey Market Oligonucleotide-based Therapies Forecast
10.6 Global Oligonucleotide-based Therapies Forecast by Type (2026-2031)
10.7 Global Oligonucleotide-based Therapies Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Oligonucleotide-based Therapies Forecast

11 KEY PLAYERS ANALYSIS

11.1 Biogen
  11.1.1 Biogen Company Information
  11.1.2 Biogen Oligonucleotide-based Therapies Product Offered
  11.1.3 Biogen Oligonucleotide-based Therapies Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Biogen Main Business Overview
  11.1.5 Biogen Latest Developments
11.2 Sarepta Therapeutics
  11.2.1 Sarepta Therapeutics Company Information
  11.2.2 Sarepta Therapeutics Oligonucleotide-based Therapies Product Offered
  11.2.3 Sarepta Therapeutics Oligonucleotide-based Therapies Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Sarepta Therapeutics Main Business Overview
  11.2.5 Sarepta Therapeutics Latest Developments
11.3 Jazz Pharmaceuticals
  11.3.1 Jazz Pharmaceuticals Company Information
  11.3.2 Jazz Pharmaceuticals Oligonucleotide-based Therapies Product Offered
  11.3.3 Jazz Pharmaceuticals Oligonucleotide-based Therapies Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Jazz Pharmaceuticals Main Business Overview
  11.3.5 Jazz Pharmaceuticals Latest Developments
11.4 Bausch & Lomb
  11.4.1 Bausch & Lomb Company Information
  11.4.2 Bausch & Lomb Oligonucleotide-based Therapies Product Offered
  11.4.3 Bausch & Lomb Oligonucleotide-based Therapies Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Bausch & Lomb Main Business Overview
  11.4.5 Bausch & Lomb Latest Developments
11.5 Alnylam Pharmaceuticals
  11.5.1 Alnylam Pharmaceuticals Company Information
  11.5.2 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Product Offered
  11.5.3 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 Alnylam Pharmaceuticals Main Business Overview
  11.5.5 Alnylam Pharmaceuticals Latest Developments
11.6 Dynavax Technologies
  11.6.1 Dynavax Technologies Company Information
  11.6.2 Dynavax Technologies Oligonucleotide-based Therapies Product Offered
  11.6.3 Dynavax Technologies Oligonucleotide-based Therapies Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 Dynavax Technologies Main Business Overview
  11.6.5 Dynavax Technologies Latest Developments
11.7 Kastle therapeutics
  11.7.1 Kastle therapeutics Company Information
  11.7.2 Kastle therapeutics Oligonucleotide-based Therapies Product Offered
  11.7.3 Kastle therapeutics Oligonucleotide-based Therapies Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 Kastle therapeutics Main Business Overview
  11.7.5 Kastle therapeutics Latest Developments
11.8 Akcea Therapeutics
  11.8.1 Akcea Therapeutics Company Information
  11.8.2 Akcea Therapeutics Oligonucleotide-based Therapies Product Offered
  11.8.3 Akcea Therapeutics Oligonucleotide-based Therapies Revenue, Gross Margin and Market Share (2020-2025)
  11.8.4 Akcea Therapeutics Main Business Overview
  11.8.5 Akcea Therapeutics Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Oligonucleotide-based Therapies Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Oligonucleotide-based Therapies Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotide
Table 4. Major Players of Aptamer
Table 5. Major Players of Other
Table 6. Oligonucleotide-based Therapies Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 7. Global Oligonucleotide-based Therapies Market Size by Type (2020-2025) & ($ millions)
Table 8. Global Oligonucleotide-based Therapies Market Size Market Share by Type (2020-2025)
Table 9. Oligonucleotide-based Therapies Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Oligonucleotide-based Therapies Market Size by Application (2020-2025) & ($ millions)
Table 11. Global Oligonucleotide-based Therapies Market Size Market Share by Application (2020-2025)
Table 12. Global Oligonucleotide-based Therapies Revenue by Player (2020-2025) & ($ millions)
Table 13. Global Oligonucleotide-based Therapies Revenue Market Share by Player (2020-2025)
Table 14. Oligonucleotide-based Therapies Key Players Head office and Products Offered
Table 15. Oligonucleotide-based Therapies Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Oligonucleotide-based Therapies Market Size by Region (2020-2025) & ($ millions)
Table 19. Global Oligonucleotide-based Therapies Market Size Market Share by Region (2020-2025)
Table 20. Global Oligonucleotide-based Therapies Revenue by Country/Region (2020-2025) & ($ millions)
Table 21. Global Oligonucleotide-based Therapies Revenue Market Share by Country/Region (2020-2025)
Table 22. Americas Oligonucleotide-based Therapies Market Size by Country (2020-2025) & ($ millions)
Table 23. Americas Oligonucleotide-based Therapies Market Size Market Share by Country (2020-2025)
Table 24. Americas Oligonucleotide-based Therapies Market Size by Type (2020-2025) & ($ millions)
Table 25. Americas Oligonucleotide-based Therapies Market Size Market Share by Type (2020-2025)
Table 26. Americas Oligonucleotide-based Therapies Market Size by Application (2020-2025) & ($ millions)
Table 27. Americas Oligonucleotide-based Therapies Market Size Market Share by Application (2020-2025)
Table 28. APAC Oligonucleotide-based Therapies Market Size by Region (2020-2025) & ($ millions)
Table 29. APAC Oligonucleotide-based Therapies Market Size Market Share by Region (2020-2025)
Table 30. APAC Oligonucleotide-based Therapies Market Size by Type (2020-2025) & ($ millions)
Table 31. APAC Oligonucleotide-based Therapies Market Size by Application (2020-2025) & ($ millions)
Table 32. Europe Oligonucleotide-based Therapies Market Size by Country (2020-2025) & ($ millions)
Table 33. Europe Oligonucleotide-based Therapies Market Size Market Share by Country (2020-2025)
Table 34. Europe Oligonucleotide-based Therapies Market Size by Type (2020-2025) & ($ millions)
Table 35. Europe Oligonucleotide-based Therapies Market Size by Application (2020-2025) & ($ millions)
Table 36. Middle East & Africa Oligonucleotide-based Therapies Market Size by Region (2020-2025) & ($ millions)
Table 37. Middle East & Africa Oligonucleotide-based Therapies Market Size by Type (2020-2025) & ($ millions)
Table 38. Middle East & Africa Oligonucleotide-based Therapies Market Size by Application (2020-2025) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Oligonucleotide-based Therapies
Table 40. Key Market Challenges & Risks of Oligonucleotide-based Therapies
Table 41. Key Industry Trends of Oligonucleotide-based Therapies
Table 42. Global Oligonucleotide-based Therapies Market Size Forecast by Region (2026-2031) & ($ millions)
Table 43. Global Oligonucleotide-based Therapies Market Size Market Share Forecast by Region (2026-2031)
Table 44. Global Oligonucleotide-based Therapies Market Size Forecast by Type (2026-2031) & ($ millions)
Table 45. Global Oligonucleotide-based Therapies Market Size Forecast by Application (2026-2031) & ($ millions)
Table 46. Biogen Details, Company Type, Oligonucleotide-based Therapies Area Served and Its Competitors
Table 47. Biogen Oligonucleotide-based Therapies Product Offered
Table 48. Biogen Oligonucleotide-based Therapies Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 49. Biogen Main Business
Table 50. Biogen Latest Developments
Table 51. Sarepta Therapeutics Details, Company Type, Oligonucleotide-based Therapies Area Served and Its Competitors
Table 52. Sarepta Therapeutics Oligonucleotide-based Therapies Product Offered
Table 53. Sarepta Therapeutics Oligonucleotide-based Therapies Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 54. Sarepta Therapeutics Main Business
Table 55. Sarepta Therapeutics Latest Developments
Table 56. Jazz Pharmaceuticals Details, Company Type, Oligonucleotide-based Therapies Area Served and Its Competitors
Table 57. Jazz Pharmaceuticals Oligonucleotide-based Therapies Product Offered
Table 58. Jazz Pharmaceuticals Oligonucleotide-based Therapies Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 59. Jazz Pharmaceuticals Main Business
Table 60. Jazz Pharmaceuticals Latest Developments
Table 61. Bausch & Lomb Details, Company Type, Oligonucleotide-based Therapies Area Served and Its Competitors
Table 62. Bausch & Lomb Oligonucleotide-based Therapies Product Offered
Table 63. Bausch & Lomb Oligonucleotide-based Therapies Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 64. Bausch & Lomb Main Business
Table 65. Bausch & Lomb Latest Developments
Table 66. Alnylam Pharmaceuticals Details, Company Type, Oligonucleotide-based Therapies Area Served and Its Competitors
Table 67. Alnylam Pharmaceuticals Oligonucleotide-based Therapies Product Offered
Table 68. Alnylam Pharmaceuticals Oligonucleotide-based Therapies Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 69. Alnylam Pharmaceuticals Main Business
Table 70. Alnylam Pharmaceuticals Latest Developments
Table 71. Dynavax Technologies Details, Company Type, Oligonucleotide-based Therapies Area Served and Its Competitors
Table 72. Dynavax Technologies Oligonucleotide-based Therapies Product Offered
Table 73. Dynavax Technologies Oligonucleotide-based Therapies Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 74. Dynavax Technologies Main Business
Table 75. Dynavax Technologies Latest Developments
Table 76. Kastle therapeutics Details, Company Type, Oligonucleotide-based Therapies Area Served and Its Competitors
Table 77. Kastle therapeutics Oligonucleotide-based Therapies Product Offered
Table 78. Kastle therapeutics Oligonucleotide-based Therapies Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 79. Kastle therapeutics Main Business
Table 80. Kastle therapeutics Latest Developments
Table 81. Akcea Therapeutics Details, Company Type, Oligonucleotide-based Therapies Area Served and Its Competitors
Table 82. Akcea Therapeutics Oligonucleotide-based Therapies Product Offered
Table 83. Akcea Therapeutics Oligonucleotide-based Therapies Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 84. Akcea Therapeutics Main Business
Table 85. Akcea Therapeutics Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Oligonucleotide-based Therapies Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Oligonucleotide-based Therapies Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Oligonucleotide-based Therapies Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Oligonucleotide-based Therapies Sales Market Share by Country/Region (2024)
Figure 8. Oligonucleotide-based Therapies Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Oligonucleotide-based Therapies Market Size Market Share by Type in 2024
Figure 10. Oligonucleotide-based Therapies in Neuromuscular Diseases
Figure 11. Global Oligonucleotide-based Therapies Market: Neuromuscular Diseases (2020-2025) & ($ millions)
Figure 12. Oligonucleotide-based Therapies in Hepatic VOD
Figure 13. Global Oligonucleotide-based Therapies Market: Hepatic VOD (2020-2025) & ($ millions)
Figure 14. Oligonucleotide-based Therapies in Other
Figure 15. Global Oligonucleotide-based Therapies Market: Other (2020-2025) & ($ millions)
Figure 16. Global Oligonucleotide-based Therapies Market Size Market Share by Application in 2024
Figure 17. Global Oligonucleotide-based Therapies Revenue Market Share by Player in 2024
Figure 18. Global Oligonucleotide-based Therapies Market Size Market Share by Region (2020-2025)
Figure 19. Americas Oligonucleotide-based Therapies Market Size 2020-2025 ($ millions)
Figure 20. APAC Oligonucleotide-based Therapies Market Size 2020-2025 ($ millions)
Figure 21. Europe Oligonucleotide-based Therapies Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Oligonucleotide-based Therapies Market Size 2020-2025 ($ millions)
Figure 23. Americas Oligonucleotide-based Therapies Value Market Share by Country in 2024
Figure 24. United States Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Oligonucleotide-based Therapies Market Size Market Share by Region in 2024
Figure 29. APAC Oligonucleotide-based Therapies Market Size Market Share by Type (2020-2025)
Figure 30. APAC Oligonucleotide-based Therapies Market Size Market Share by Application (2020-2025)
Figure 31. China Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 35. India Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Oligonucleotide-based Therapies Market Size Market Share by Country in 2024
Figure 38. Europe Oligonucleotide-based Therapies Market Size Market Share by Type (2020-2025)
Figure 39. Europe Oligonucleotide-based Therapies Market Size Market Share by Application (2020-2025)
Figure 40. Germany Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 41. France Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Oligonucleotide-based Therapies Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Oligonucleotide-based Therapies Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Oligonucleotide-based Therapies Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Oligonucleotide-based Therapies Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 54. APAC Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 55. Europe Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 57. United States Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 58. Canada Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 59. Mexico Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 60. Brazil Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 61. China Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 62. Japan Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 63. Korea Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 65. India Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 66. Australia Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 67. Germany Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 68. France Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 69. UK Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 70. Italy Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 71. Russia Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 72. Egypt Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 73. South Africa Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 74. Israel Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 75. Turkey Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)
Figure 76. Global Oligonucleotide-based Therapies Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Oligonucleotide-based Therapies Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Oligonucleotide-based Therapies Market Size 2026-2031 ($ millions)